Evidence map›Paper›PMID 42395721›Full record

ArticleRSC advances2026

Identification of selective

Zahra Batool, Halil Şenol, Rushba Saman Masood, Tugce Salduz, Fatma Betul Yoladi, Fahri Akbas, Feyzi Sinan Tokali, Norah A Albekairi, Asif Rasool, Zahid Shafiq and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zahra BatoolInstitute of Chemical Sciences, Bahauddin Zakariya University Multan 60800 Pakistan zahidshafiq@bzu.edu.pk.
Halil ŞenolDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University Fatih Istanbul 34093 Turkiye.
Rushba Saman MasoodDepartment of Chemistry, Quaid i Azam University Islamabad 45320 Pakistan.
Tugce SalduzDepartment of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Üsküdar University 34662 Istanbul Turkiye.
Fatma Betul YoladiDepartment of Pharmaceutical Toxicology, Faculty of Pharmacy, Atatürk University 25240 Erzurum Turkiye.
Fahri AkbasDepartment of Medical Biology, Faculty of Medicine, Bezmialem Vakif University Fatih Istanbul 34093 Turkiye.
Feyzi Sinan TokaliDepartment of Material and Material Processing Technologies, Kars Vocational School, Kafkas University 36100 Kars Turkiye.
Norah A AlbekairiDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University Post Box 2455 Riyadh 11451 Saudi Arabia.
Asif RasoolSchool of Chemistry and Chemical Engineering, Nanjing University Nanjing 210093 China.
Zahid ShafiqInstitute of Chemical Sciences, Bahauddin Zakariya University Multan 60800 Pakistan zahidshafiq@bzu.edu.pk.ORCID https://orcid.org/0000-0003-4088-8297
Abdulrahman AlshammariDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University Post Box 2455 Riyadh 11451 Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains one of the leading causes of cancer-related mortality worldwide and necessitates the development of novel targeted agents. In this study, a series of new thiosemicarbazone derivatives (5a-r) were synthesized and evaluated for their anticancer potential through combined

Identifiers

PMID42395721
PMCPMC13326682

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.